Wedbush Raises Vor Biopharma (NASDAQ:VOR) Price Target to $15.00

Vor Biopharma (NASDAQ:VOR) had its price target hoisted by analysts at Wedbush to $15.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Wedbush’s price target suggests a potential downside of 13.74% from the company’s previous close.

Several other research firms have also weighed in on VOR. JPMorgan Chase & Co. cut their target price on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. Jefferies Financial Group began coverage on Vor Biopharma in a research report on Monday. They set a “buy” rating and a $50.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Wells Fargo & Company started coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, TD Cowen assumed coverage on shares of Vor Biopharma in a report on Wednesday, December 17th. They set a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $50.67.

Vor Biopharma Stock Down 2.5%

NASDAQ:VOR opened at $17.39 on Tuesday. Vor Biopharma has a 12-month low of $2.62 and a 12-month high of $65.80. The firm has a market capitalization of $181.03 million, a P/E ratio of -0.04 and a beta of 1.91. The stock’s fifty day simple moving average is $14.18 and its 200-day simple moving average is $17.73.

Institutional Investors Weigh In On Vor Biopharma

Several large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new stake in Vor Biopharma in the 4th quarter valued at $36,000. Squarepoint Ops LLC acquired a new position in shares of Vor Biopharma during the third quarter worth about $230,000. Bank of America Corp DE grew its holdings in shares of Vor Biopharma by 679.3% during the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock worth $232,000 after buying an additional 4,144 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Vor Biopharma by 497.3% during the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after buying an additional 5,058 shares in the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in Vor Biopharma in the 3rd quarter valued at approximately $304,000. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).